Search

everythinglearnresearchcommunity

for

Search:↓

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The user has been using minoxidil for over a year with little success, added tretinoin cream, and is considering adding red light therapy. They are advised to use moisturizer to counteract skin sensitivity from tretinoin.

The conversation discusses a hair loss and scalp care routine involving ciclopirox shampoo, benzoyl peroxide, clindamycin gel, clobetasol propionate, and calcipotriol to manage seborrheic dermatitis, folliculitis, and inflammation. It also touches on the role of diet and other treatments like oral minoxidil and pioglitazone for scalp health.

The user experienced noticeable hair regrowth, especially at the hairline, after using Minoxidil, microneedling, vitamins, and specific shampoos for 2-3 months. They are considering adding finasteride but are hesitant due to potential side effects.

Concerns about metal particles from dermapen or dermaroller needles potentially entering the skin and lymph nodes, similar to tattoo needles. Discussion includes the possibility of using Minoxidil, finasteride, and RU58841 for hair loss treatment.

Creating a liposomal gel with Pyrilutamide for hair loss to reduce systemic effects, similar to Xyon's gel. The discussion includes concerns about ingredient sourcing and the benefits of targeted topical treatments.

A user experienced high estrogen levels after 10 months of taking 1mg oral finasteride but is happy with hair regrowth. They are considering switching to topical finasteride and are also taking DIM and Zinc supplements.

After a second session of Platelet-Rich Plasma (PRP) treatment for hair regrowth, the user is experiencing increased shedding of thick and dark hairs and is concerned about whether this is temporary. They are seeking others' experiences with PRP, specifically regarding the duration of shedding and eventual positive outcomes.

The conversation discusses microneedling for hair loss, with the original poster experiencing pinpoint bleeding after using needles of 1.25mm and 0.5mm, possibly due to adding GHK-Cu to their treatment regimen. They are inquiring if others bleed at similar depths.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

The user experienced chronic telogen effluvium and mild male pattern baldness, treated with finasteride, oral minoxidil, and later switched to dutasteride, which stopped excessive hair shedding. Other treatments like low-level laser therapy, hair loss shampoos (except ketoconazole), and supplements were ineffective.

OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A user shared their successful hair loss treatment using 1.25mg finasteride daily, 2.5mm microneedling every 1-3 weeks, zinc pyrithione shampoo, occasional scalp massages, and 40% glycolic acid on temples. They reported significant progress over 21 months.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Copper peptides may help with hair thickness and health, but their effectiveness in reducing DHT is uncertain. Minoxidil is being used, but finasteride is not available due to legal restrictions; ketoconazole shampoo is recommended for managing Malassezia-related issues.

The conversation discusses whether applying topical Dutasteride right after microneedling could be as effective as mesotherapy for hair loss treatment. The user believes it makes sense and seeks opinions on this approach.

The user is experiencing severe hair shedding after using RU58841, stemoxydine, and minoxidil, and has stopped using finasteride due to side effects. They hope the shedding is temporary and will lead to regrowth.

OP saw positive results from 4 months of finasteride, vitamin D3, and microneedling. They plan to add rosemary and castor oil but decided against using minoxidil.

The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.

The user has been using oral finasteride daily, topical minoxidil twice a day, tretinoin once a week, and 2% ketoconazole twice a week since February 5th. They shared progress pictures showing hair improvement over two and a half months.

The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.

Lighting can significantly affect the perception of hair progress in photos. The user has been using dutasteride and oral minoxidil for hair loss, noting improvements after switching from finasteride.

OP saw significant hair growth after starting scalp exfoliation and using 5% topical minoxidil for 4.5 months, along with microneedling initially. Users discussed the benefits of exfoliation and inquired about experiences with finasteride and dutasteride.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

A 40-year-old used minoxidil, dutasteride, RU58841, and microneedling for one year, resulting in noticeable hair regrowth despite initial shedding. They believe having more hair is beneficial for dating at their age and also recommend staying fit, eating well, and sleeping over 8 hours.

The user experienced hair loss after switching to daily microneedling and stopping tretinoin, while continuing oral finasteride, minoxidil, and other treatments. The consensus suggests daily microneedling is excessive and harmful, recommending less frequent sessions to allow healing.